Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

FGFR2 (Fibroblast growth factor receptor 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FoundationOne® CDx (110)

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue CGP Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® FGFR2 Break-apart FISH Probe Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Myeloid Kit

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Solid Tumor Kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

GALEAS™ Tumor

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

Labcorp® Plasma Focus™

LiquidHALLMARK®

LiquidMARK™ Bile Duct test

NeXT Dx™ Test

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

Resolution ctDx Lung Assay™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

StrataNGS™ Test

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Fusion LBx Panel

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

FoundationOne® CDx (110)

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue CGP Kit

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® FGFR2 Break-apart FISH Probe Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Myeloid Kit

Archer® FusionPlex® Oncology Research Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer® VariantPlex® Solid Tumor Kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

GALEAS™ Tumor

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

Labcorp® Plasma Focus™

LiquidHALLMARK®

LiquidMARK™ Bile Duct test

NeXT Dx™ Test

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

Resolution ctDx Lung Assay™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

StrataNGS™ Test

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Fusion LBx Panel

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

›

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Biliary Tract Cancer	FGFR2 fusion	Biliary Tract Cancer	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2
FGFR2b overexpression + HER-2 negative	Gastric Cancer	FGFR2b overexpression + HER-2 negative	Gastric Cancer	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B
FGFR2b overexpression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	FGFR2b overexpression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B	AMG 552 Sensitive: B - Late Trials AMG 552 Sensitive : B
FGFR2 fusion	Urothelial Cancer	FGFR2 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B